{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fed&page=3",
    "query": {
      "intervention": "Fed",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1101,
    "total_pages": 111,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fed&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fed&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T09:15:27.743Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02608320",
      "title": "A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Duragesic (Fentanyl Transdermal System [TDS] Small Patches)",
          "type": "DRUG"
        },
        {
          "name": "New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)",
          "type": "DRUG"
        },
        {
          "name": "Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)",
          "type": "DRUG"
        },
        {
          "name": "Duragesic (Fentanyl TDS Large Patches)",
          "type": "DRUG"
        },
        {
          "name": "New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)",
          "type": "DRUG"
        },
        {
          "name": "Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2015-11-17",
      "completion_date": "2016-04-13",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02608320"
    },
    {
      "nct_id": "NCT02370485",
      "title": "A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY2801653",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 23,
      "start_date": "2015-02",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-06-19",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370485"
    },
    {
      "nct_id": "NCT01698840",
      "title": "Effect of Vitamin D in Diets of Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Premature Infants"
      ],
      "interventions": [
        {
          "name": "Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 39,
      "start_date": "2013-01",
      "completion_date": "2016-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01698840"
    },
    {
      "nct_id": "NCT06477926",
      "title": "A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-668 IR",
          "type": "DRUG"
        },
        {
          "name": "ABBV-668 ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2024-07-09",
      "completion_date": "2024-09-20",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06477926"
    },
    {
      "nct_id": "NCT03404817",
      "title": "Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Original formulation EMB-001",
          "type": "DRUG"
        },
        {
          "name": "New formulation EMB-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Embera NeuroTherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 9,
      "start_date": "2018-03-01",
      "completion_date": "2018-06-07",
      "has_results": false,
      "last_update_posted_date": "2018-06-11",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03404817"
    },
    {
      "nct_id": "NCT06860243",
      "title": "A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Opevesostat",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Fludrocortisone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2025-05-13",
      "completion_date": "2026-02-19",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06860243"
    },
    {
      "nct_id": "NCT00778284",
      "title": "Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ranbaxy Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2002-10",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2008-10-23",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778284"
    },
    {
      "nct_id": "NCT04980833",
      "title": "Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-related Overgrowth Spectrum (PROS)"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "2 Years to 100 Years"
      },
      "enrollment_count": 41,
      "start_date": "2022-01-27",
      "completion_date": "2027-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980833"
    },
    {
      "nct_id": "NCT00647608",
      "title": "Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Propranolol Hydrochloride Extended-Release Capsules 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Inderal® LA Capsules 160 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2005-09",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00647608"
    },
    {
      "nct_id": "NCT04246333",
      "title": "Duodenal Feeds in Very Low Birth Weight Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BPD - Bronchopulmonary Dysplasia",
        "VLBW - Very Low Birth Weight Infant",
        "Feeding Disorder Neonatal",
        "Feeding; Difficult, Newborn",
        "Premature Birth",
        "Chronic Lung Disease of Prematurity"
      ],
      "interventions": [
        {
          "name": "Mode of Delivery of Feeds",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins All Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "0 Days to 12 Months"
      },
      "enrollment_count": 24,
      "start_date": "2020-08-07",
      "completion_date": "2026-02-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-17T09:15:27.743Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04246333"
    }
  ]
}